Hatchery Vaccination Quality Control of Herpesvirus of Turkey-Infectious Bursal Disease HVT-IBD Viral Vector Vaccine Application by Specific qPCR

2012 ◽  
Vol 11 (9) ◽  
pp. 570-576 ◽  
Author(s):  
Stephane Lemiere ◽  
Francisco Perozo ◽  
Blandine de Saint-Vis ◽  
Jennifer Diasparra ◽  
Arnaud Carlotti ◽  
...  
Keyword(s):  
Quality Control ◽  
Viral Vector ◽  
Infectious Bursal Disease ◽  
Vector Vaccine ◽  
Bursal Disease ◽  
Viral Vector Vaccine

scholarly journals Effective inhibition of infectious bursal disease virus replication by recombinant avian adeno-associated virus-delivered microRNAs

2009 ◽  
Vol 90 (6) ◽  
pp. 1417-1422 ◽  
Author(s):  
Yongjuan Wang ◽  
Huaichang Sun ◽  
Pengpeng Shen ◽  
Xinyu Zhang ◽  
Xiaoli Xia
Keyword(s):  
Disease Virus ◽  
Infectious Bursal Disease Virus ◽  
Viral Vector ◽  
Infectious Bursal Disease ◽  
Inhibitory Effects ◽  
Rt Pcr ◽  
Adeno Associated Virus ◽  
Rnai Technology ◽  
Bursal Disease ◽  
In Cells

RNA interference (RNAi) is a novel antiviral strategy against a variety of virus infections. Infectious bursal disease virus (IBDV) causes an economically important disease in young chickens. This study demonstrated efficient inhibition of IBDV replication by recombinant avian adeno-associated virus (rAAAV)-delivered anti-VP1 and anti-VP2 microRNAs (miRNAs). In the viral vector-transduced cells, sequence-specific miRNA expression was detected by poly(A)-tailed RT-PCR. Reporter assays using a pVP2-EGFP vector showed significant and long-lasting inhibition of VP2–EGFP expression in cells transduced with anti-VP2 miRNA-expressing rAAAV-RFPmiVP2E, but not with the control miRNA-expressing rAAAV-RFPmiVP2con or anti-VP1 miRNA-expressing rAAAV-RFPmiVP1. Semi-quantitative RT-PCR and/or virus titration assays showed a significant inhibitory effect on homologous IBDV replication in cells transduced with rAAAV-RFPmiVP1 or rAAAV-RFPmiVP2E. For two heterologous IBDV isolates, transduction with rAAAV-RFPmiVP1 led to slightly weaker but similar inhibitory effects, whereas transduction with rAAAV-RFPmiVP2E resulted in significantly weaker and different inhibitory effects. These results suggest that rAAAV could act as an efficient vector for miRNA delivery into avian cells and that VP1 is the more suitable target for interfering with IBDV replication using RNAi technology.

scholarly journals Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19

2021 ◽  
Vol 8 ◽  
Author(s):  
Rajashri Bezbaruah ◽  
Pobitra Borah ◽  
Bibhuti Bhushan Kakoti ◽  
Nizar A. Al-Shar’I ◽  
Balakumar Chandrasekaran ◽  
...  
Keyword(s):  
Viral Vectors ◽  
Ebola Virus ◽  
Vaccine Development ◽  
Viral Vector ◽  
World Health ◽  
Prolonged Incubation ◽  
Vaccine Candidates ◽  
Vector Vaccine ◽  
Dna And Rna ◽  
Viral Vector Vaccine

Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, arose at the end of 2019 as a zoonotic virus, which is the causative agent of the novel coronavirus outbreak COVID-19. Without any clear indications of abatement, the disease has become a major healthcare threat across the globe, owing to prolonged incubation period, high prevalence, and absence of existing drugs or vaccines. Development of COVID-19 vaccine is being considered as the most efficient strategy to curtail the ongoing pandemic. Following publication of genetic sequence of SARS-CoV-2, globally extensive research and development work has been in progress to develop a vaccine against the disease. The use of genetic engineering, recombinant technologies, and other computational tools has led to the expansion of several promising vaccine candidates. The range of technology platforms being evaluated, including virus-like particles, peptides, nucleic acid (DNA and RNA), recombinant proteins, inactivated virus, live attenuated viruses, and viral vectors (replicating and non-replicating) approaches, are striking features of the vaccine development strategies. Viral vectors, the next-generation vaccine platforms, provide a convenient method for delivering vaccine antigens into the host cell to induce antigenic proteins which can be tailored to arouse an assortment of immune responses, as evident from the success of smallpox vaccine and Ervebo vaccine against Ebola virus. As per the World Health Organization, till January 22, 2021, 14 viral vector vaccine candidates are under clinical development including 10 nonreplicating and four replicating types. Moreover, another 39 candidates based on viral vector platform are under preclinical evaluation. This review will outline the current developmental landscape and discuss issues that remain critical to the success or failure of viral vector vaccine candidates against COVID-19.

Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster

2018 ◽  
Vol 63 (2) ◽  
pp. 368-374
Author(s):  
Guanbo Wang ◽  
Longzheng Yu ◽  
Artemis Efstratiou ◽  
Paul Franck Adjou Moumouni ◽  
Mingming Liu ◽  
...  
Keyword(s):  
Protective Effect ◽  
Plasmid Dna ◽  
Viral Vector ◽  
Recombinant Adenovirus ◽  
Vaccination Strategy ◽  
Challenge Infection ◽  
Babesia Microti ◽  
Post Challenge ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

AbstractIn the present study, we have investigated the protective effect of a heterologous prime-boost strategy with priming plasmid DNA followed by recombinant adenovirus, both expressing BmAMA1, againstBabesia microtiinfection. Four groups consisting of 3 hamsters per group were immunized with pBmAMA1/Ad5BmAMA1, pNull/Ad5BmAMA1, pBmAMA1/Ad5Null and pNull/Ad5Null, followed by challenge infection withB.microti. Our results showed that hamsters immunized with plasmid and adenovirus expressing BmAMA1 developed a robust IgG and IgG2a antibody response against BmAMA1, suggesting the DNA vaccine or viral vector vaccine tend to induce a Th1-biased response. Compared to the control hamsters, the hamsters vaccinated either with the prime-boost strategy or one of the two “vaccines” exhibited no significant protection againstB.microtichallenge. Although a slight difference in terms of parasitemia and hematocrit values at days 14–16 post challenge infection was observed, no other statistical difference was detected. Our results indicate that the prime-boost vaccination strategy of injection of plasmid and adenovirus expressing BmAMA1 is not efficient in protecting againstB.microtiinfection.

scholarly journals Safety of the novel influenza viral vector Brucella abortus vaccine in pregnant heifers

2015 ◽  
Vol 46 (1) ◽  
pp. 114-118 ◽  
Author(s):  
Kaissar Tabynov ◽  
Sholpan Ryskeldinova ◽  
Zhailaubay Kydyrbayev ◽  
Abylai Sansyzbay
Keyword(s):  
Brucella Abortus ◽  
Viral Vector ◽  
Booster Vaccination ◽  
Positive Control ◽  
Control Group ◽  
The Novel ◽  
Subcutaneous Route ◽  
Control Groups ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

ABSTRACT: The present study provides the first information about the safety of a new influenza viral vector vaccine expressing the Brucella ribosomal protein L7/L12 or Omp16 containing the adjuvant Montanide Gel01 in pregnant heifers. Immunization of pregnant heifers was conducted via the conjunctival (n=10) or subcutaneous (n=10) route using cross prime and booster vaccination schedules at an interval of 28 days. The vector vaccine was evaluated in comparison with positive control groups vaccinated with B. abortus S19 (n=10) or B. abortus RB51 (n=10) and a negative (PBS+Montanide Gel01; n=10) control group. Clinical studies, thermometry, assessment of local reactogenicity and observation of abortion showed that the vector vaccine via the conjunctival or subcutaneous route was completely safe for pregnant heifers compared to the commercial vaccines B. abortus S19 or B. abortus RB51. The only single adverse event was the formation of infiltration at the site of subcutaneous injection; this reaction was not observed for the conjunctival route.

Compatibility of Turkey Herpesvirus–Infectious Bursal Disease Vector Vaccine with Marek's Disease Rispens Vaccine Injected into Day-Old Pullets

2011 ◽  
Vol 6 (1) ◽  
pp. e28-e29 ◽  
Author(s):  
Stephane Lemiere ◽  
Siam Yit Wong ◽  
Anne-Lise Saint-Gerand ◽  
Sylvain Goutebroze ◽  
François-Xavier Le Gros
Keyword(s):  
Marek's Disease ◽  
Infectious Bursal Disease ◽  
Marek’S Disease ◽  
Vector Vaccine ◽  
Disease Vector ◽  
Bursal Disease

scholarly journals Cutting Edge: Mucosal Application of a Lyophilized Viral Vector Vaccine Confers Systemic and Protective Immunity toward Intracellular Pathogens

2009 ◽  
Vol 182 (5) ◽  
pp. 2573-2577 ◽  
Author(s):  
Wolfgang Kastenmuller ◽  
Georg Gasteiger ◽  
Leon Stross ◽  
Dirk H. Busch ◽  
Ingo Drexler
Keyword(s):  
Protective Immunity ◽  
Viral Vector ◽  
Cutting Edge ◽  
Intracellular Pathogens ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

Field efficacy of different vaccines against infectious bursal disease in broiler flocks

2011 ◽  
Vol 59 (3) ◽  
pp. 385-398 ◽  
Author(s):  
Olga Zorman Rojs ◽  
Uroš Krapež ◽  
Brigita Slavec ◽  
Rahela Juršič-Cizerl ◽  
Tea Poljanec
Keyword(s):  
Immune Response ◽  
Bursa Of Fabricius ◽  
Infectious Bursal Disease ◽  
Risk Area ◽  
Vector Vaccine ◽  
Humoral Immune ◽  
Production Parameters ◽  
Bursal Disease ◽  
Antibody Titres ◽  
High Level

A field study was performed to determine the efficacy of three commercially available vaccines against infectious bursal disease (IBD) in commercial broilers raised in a high IBD virus (IBDV) risk area. Live attenuated intermediate and intermediate plus vaccines were used in four flocks. Birds were vaccinated orally at the estimated vaccination time. Three broiler flocks were vaccinated subcutaneously with a turkey herpesvirus (HVT)-IBD vector vaccine at one day old. Evaluation of the efficacy of different vaccines was focused on humoral immune response, bursa/body weight (B/Bw) ratio, molecular detection of IBDV in ileocaecal tonsils and bursa of Fabricius, and production parameters. The serological results showed that although the uptake of all three vaccine strains was confirmed in the lymphoid organs, no significant antibody response to vaccination was detected in flocks vaccinated with intermediate and intermediate plus vaccines. A significant increase in antibody titres detected in flocks vaccinated with the vector vaccine indicated its ability to induce an immune response in birds with a high level of maternally derived antibodies. Observations obtained in this field trial did not confirm the expected reduction of the B/Bw ratio in flocks vaccinated with less attenuated vaccines. No significant differences were observed between birds vaccinated with the vector vaccine and those immunised with the intermediate plus vaccine. Very virulent IBDV was confirmed in the flock vaccinated with the intermediate vaccine. The infection induced reduced B/Bw and moderate mortality but did not affect the production parameters. Field infection was not detected in broilers vaccinated with the intermediate plus vaccine and the vector vaccine.

Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine

Cornea ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Tanveer Alam Khan ◽  
Navneet Sidhu ◽  
Livia Khan ◽  
Seema Sen ◽  
Nishat Hussain ◽  
...  
Keyword(s):  
Viral Vector ◽  
Vector Vaccine ◽  
Immune Mediated ◽  
Viral Vector Vaccine
Sign in / Sign up

Export Citation Format

Share Document